Helix BioMedix, Inc. (OTCBB: HXBM), a developer of bioactive peptides, announced that the Company entered into an agreement with RubyDerm Bio, Inc. under which RubyDerm will assume responsibility, on an exclusive basis, for the distribution of certain of Helix BioMedix’s branded prestige skin care products to spas, beauty stores, hospitals, clinics, physicians, and consumers in South Korea, China and Japan.
“We are delighted to expand our distribution though this partnership.”
"RubyDerm Bio gives the Company access to three of the major Asian aesthetic and dermatology markets," said R. Stephen Beatty, President and CEO of Helix BioMedix. "We are delighted to expand our distribution though this partnership."
Jerry Jung, President and CEO of RubyDerm Bio, said, "Helix BioMedix has a proven peptide technology base for effective skin care backed by impressive science. We are happy to bring the Cerakine™ brand of skin health products to the South Korean, Chinese and Japanese aesthetic medical markets."
The four-year agreement includes certain minimum purchases and may be extended through mutual agreement.